Ribbskottet
VC Fund
Stockholm, Sweden
Ribbskottet is an investment company.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Ribbskottet invests in
Health CareBiotechnologyMedicalHospitalMedical Device
Stages Ribbskottet invests in
Post-IPO EquityConvertible Note
Countries Ribbskottet invests in
Sweden
Investment Focus
Industry
- Health Care 2 (50%)
- Biotechnology 2 (50%)
- Medical 1 (25%)
- Hospital 1 (25%)
- Medical Device 1 (25%)
Stage
- Post-IPO Equity 1 (25%)
- Convertible Note 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Umecrine Cognition
|
Umecrine Cognition develops drugs against central nervous system neurological disorders, CNS caused by endogenous CNS active steroids (GABA steroids).Umecrine Cognition is a lean organization in a competent network. Together with Karolinska Development, the company was founded in 2006 as a subsidiary to Umecrine AB, in order to focus thedevelopment activities on finding treatments for neurological disorders in the central nervous system that are caused by endogenous CNS-active steroids (GABA-steroids).The GABA-system is the major inhibitory neurotransmitter system within the central nervous system and an excessive GABAergic tone has been described in several important clinical conditions such as Hepatic Encephalopathy, Alzheimer’s disease, and Down syndrome. Certain endogenous GABA-steroids act as strong agonists at the GABAA receptor and alterations in the production and metabolism of these GABA-steroids has been described in Hepatic Encephalopathy, Alzheimer’s disease, and Down syndrome.The company is focusing its efforts on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease. | $2.6M / Convertible Note / Jul 14, 2025 | |
SciBase
|
Founded in 1998, SciBase AB is a Swedish medical technology company, headquartered in Stockholm, that has developed a unique point of care device for the accurate detection of malignant melanoma.The Scibase method is based on a technology called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of humantissue to categorize cellular structures and thereby detect malignancies. Nevisense is a point-of-care device that has emerged from more than 20 years of academic research at Karolinska Institutet Stockholm and significantly increases the physician’s ability to detect and monitor skin tissue alterations. Nevisense has strong protections through a comprehensive patent portfolio and several other combined approaches that relate to technical and clinical development. | $1.1M / Post-IPO Equity / Jun 23, 2025 | |
|
Umecrine Cognition
|
Umecrine Cognition develops drugs against central nervous system neurological disorders, CNS caused by endogenous CNS active steroids (GABA steroids).Umecrine Cognition is a lean organization in a competent network. Together with Karolinska Development, the company was founded in 2006 as a subsidiary to Umecrine AB, in order to focus thedevelopment activities on finding treatments for neurological disorders in the central nervous system that are caused by endogenous CNS-active steroids (GABA-steroids).The GABA-system is the major inhibitory neurotransmitter system within the central nervous system and an excessive GABAergic tone has been described in several important clinical conditions such as Hepatic Encephalopathy, Alzheimer’s disease, and Down syndrome. Certain endogenous GABA-steroids act as strong agonists at the GABAA receptor and alterations in the production and metabolism of these GABA-steroids has been described in Hepatic Encephalopathy, Alzheimer’s disease, and Down syndrome.The company is focusing its efforts on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease. | $2.2M / Convertible Note / Dec 19, 2024 | |
|
Umecrine Cognition
|
Umecrine Cognition develops drugs against central nervous system neurological disorders, CNS caused by endogenous CNS active steroids (GABA steroids).Umecrine Cognition is a lean organization in a competent network. Together with Karolinska Development, the company was founded in 2006 as a subsidiary to Umecrine AB, in order to focus thedevelopment activities on finding treatments for neurological disorders in the central nervous system that are caused by endogenous CNS-active steroids (GABA-steroids).The GABA-system is the major inhibitory neurotransmitter system within the central nervous system and an excessive GABAergic tone has been described in several important clinical conditions such as Hepatic Encephalopathy, Alzheimer’s disease, and Down syndrome. Certain endogenous GABA-steroids act as strong agonists at the GABAA receptor and alterations in the production and metabolism of these GABA-steroids has been described in Hepatic Encephalopathy, Alzheimer’s disease, and Down syndrome.The company is focusing its efforts on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease. | $2.9M / Convertible Note / Nov 17, 2023 |
Co-Investors
AB Ility
3 deals together
Karolinska
3 deals together
Haga Gruppen
1 deal together
Life Science Invest Fund
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Medical Device Investors
11,047 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
FAQ
What does Ribbskottet invest in?
Ribbskottet invests primarily in Health Care, Biotechnology and Medical startups, most often at Post-IPO Equity and Convertible Note stage. Most of the 4 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Ribbskottet last invest?
The most recent investment recorded for Ribbskottet closed in Jul 2025. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
